Journal article icon

Journal article

Safety and tolerability of pioglitazone

Abstract:

Pioglitazone HCl, a new thiazolidinedione (TZD), has been developed for the treatment of type 2 diabetes. The drug was tested in several trials that included over 5,000 subjects. Of these, over 3,500 subjects received active treatment. At doses between 15-45 mg pioglitazone was well tolerated with dropouts due to adverse events being similar in pioglitazone and placebo groups. The main side effect of treatment was mild to moderate peripheral oedema. Oedema was not associated with signs or sym...

Expand abstract
Publication status:
Published

Actions


Authors


Belcher, G More by this author
Matthews, DR More by this author
Journal:
EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY and DIABETES
Volume:
108
Issue:
SUPPL. 2
Pages:
S267-S273
Publication date:
2000
ISSN:
0947-7349
URN:
uuid:0525d0af-e64d-4251-830b-b00a22696319
Source identifiers:
73006
Local pid:
pubs:73006
Language:
English
Keywords:

Terms of use


Metrics



If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP